Manuscripts
Showing 1559 manuscripts.
Efficacy, safety, and tolerability of dispersible and immediate release abacavir/dolutegravir/lamivudine tablets in children with HIV: IMPAACT 2019 week 48 results
Citation
Helena Rabie, Dwight E. Yin, Shawn Ward, Yasha Rani, Lauren Ziemba, Kristina M. Brooks, Tim R. Cressey, Gaerolwe R. Masheto, Haseena Cassim, Jaime G. Deville, Ponego L. Ponatshego, Faeezah Patel, Linda Aurpibul, Shaun L. Barnabas, Iris Mustich, Anne Coletti, Barbara Heckman, Chelsea Krotje, Ellen Townley, Jack Moye, Sai Majji, Edward P. Acosta, Kevin Ryan, Hardik Chandasana, Cynthia H. Brothers, Ann M. Buchanan, Patricia M. Flynn, IMPAACT 2019 Study Team. Efficacy, safety, and tolerability of dispersible and immediate release abacavir/dolutegravir/lamivudine tablets in children with HIV: IMPAACT 2019 week 48 results. 2025. PMID: 40440679Year
2025
Study
IMPAACT 2019
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study
Citation
Mark F Cotton, Patrick Jean-Philippe, Anne Coletti, Ellen G Chadwick, Jennifer Jao, Stephen A Spector, Mark Mirochnick, Edmund V Capparelli, Diane Costello, Joseph Szewczyk, Nicol Nicodimus, Lynda Stranix-Chibanda, Adeodata R Kekitiinwa, Violet Korutaro, Deborah Persaud, Christina Reding, Yvonne Bryson, Mary N Carrington, Bryan S Nelson, Sai Majji, Camlin Tierney, Dwight E Yin. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study. Lancet HIV. 2024. 23: 2352-3018. PMID: 38061376Year
2024
Journal
Lancet HIV
Study
P1115
Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum
Citation
Risa M. Hoffman, Sean Brummel, Lauren Ziemba, Lameck Chinula, Jeffrey S A Stringer, Frances Nakayiwa, Avy Violari, Lee Fairlie, Victoria Ndyanabangi, Teacler G. Nematadzira, Sherika Hanley, Esau João, Linda Aurpibul, Mario Dias Correa Junior, Oranich Navanukroh, Neetal Nevrekar, Gerhard Theron, Cristina Barroso Hofer, Rebecca Zash, Roger Shapiro, Nahida Chakhtoura, Ben Johnston, Chelsea Krotje, Katie McCarthy, Patrick Jean-Philippe, Paul Sax, Judith S. Currier, Shahin Lockman, VESTED Study Team. Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum. Clinical Infectious Diseases. 2024. 78: 1617-1628. PMID: 38180851Year
2024
Journal
Clinical Infectious Diseases
Study
IMPAACT 2010
Pharmacokinetics and Safety of Remdesivir in Pregnant and Non-Pregnant Women with COVID: Results from IMPAACT 2032
Citation
Sharon Nachman, Frederic Bone, Jennifer Jao, Kira Bacon, Murli Purswani, Benjamin Johnston, Allison Agwu, Christina Reding, Christy Beneri, Kathryn Kersey, Jaime G. Deville, Rita Humeniuk, Kathleen Powis, Brookie M. Best, Alice M. Stek, Mark Mirochnick, Ahizechukwu Eke, Jeremiah D. Momper, David E. Shapiro, IMPAACT 2032 Study Team, Edmund Capparelli, Elizabeth Greene, Kathleen George, Kristina M. Brooks, Dwight E. Yin, Kristin Baltrusaitis, Patrick Jean-Philippe, Diana F. Clarke, Nahida Chakhtoura. Pharmacokinetics and Safety of Remdesivir in Pregnant and Non-Pregnant Women with COVID: Results from IMPAACT 2032. Journal of Infectious Diseases. 2024. 230: 878-888. PMID: 38839047Year
2024
Journal
Journal of Infectious Diseases
Study
IMPAACT 2032
Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1
Citation
Hardik Chandasana, Sven C. van Dijkman, Rashmi Mehta, Mark Bush, Helena Rabie, Patricia Flynn, Tim R. Cressey, Edward P. Acosta, Kristina M. Brooks, IMPAACT 2019 Study Team. Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1. Infectious Diseases and Therapy. 2024. PMID: 38961048Year
2024
Journal
Infectious Diseases and Therapy
Study
IMPAACT 2019
Impact of in-utero exposure to HIV and latent TB on infant humoral responses
Citation
Jyoti Mathad, Grace Montepiedra, Amita Gupta, Savita Pahwa, Kimberly J.S. Hjelmar, Lesley R. de Armas, Evan Goldberg, Suresh Pallikkuth. Impact of in-utero exposure to HIV and latent TB on infant humoral responses. Frontiers in Immunology. 2024. 15: 1423435. PMID: 38994354Year
2024
Journal
Frontiers in Immunology
Study
P1078
Characterising HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial
Citation
Kevin Knowles, Lauren Ziemba, Sean Bremmel, Anne Coletti, Patrick Jean Philippe, Nahida Chakhtoura, Tichaona Vhembo, Haseena Cassim, Maxensia Owor, Lee Fairlie, Sikhulile Moyo, Violet Korutaro, Lameck Chinula, Marley D. Bishop, Shahin Lockman, Ceejay L. Boyce, Lisa M. Frenkel, Ingrid A. Beck, IMPAACT 2010 Team, Sheila M. Styrchak. Characterising HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial. Journal of International AIDS Society. 2024. 96: 385-392. PMID: 39175843Year
2024
Journal
Journal of International AIDS Society
Study
IMPAACT 2010
Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants
Citation
Benjamin Johnston, Terence Mohammed, Tichaona Vhembo, Enid Kabugho, Gerald Agaba Muzorah, Haseena Cassim, Lee Fairlie, Elizabeth S. Machado, Denise L. Jacobson, James S. Ngocho, Krista S. Crider, Roger L. Shapiro, Patricia DeMarrais, Lena Serghides, Sean Brummel, Nahida Chakhtoura, Mindy Zhang, Lameck Chinula, Christine M. Pfeiffer, Shahin Lockman, Cynthia A. Moore, Katie McCarthy. Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants. Journal of Infectious Diseases. 2024. 230: 1224-1234. PMID: 38877762Year
2024
Journal
Journal of Infectious Diseases
Study
IMPAACT 2010
Markers of maternal bone and renal toxicity through 50 weeks postpartum: IMPAACT 2010 (VESTED) Trial
Citation
Laarni Igawa, Paul E. Sax, Anne Coletti, Lynda Stranix-Chibanda, Dorinda Mukura, IMPAACT 2010/VESTED study team and investigators, Lindie Rossouw, Gerhard Theron, Chelsea Krotje, Patrick Jean-Philippe, Nahida Chakhtoura, Haseena Cassim, Sisinyana Ruth Mathiba, Joel Maena, Gaerolwe Masheto, William Murtaugh, Sean S Brummel, Lee Fairlie, Lauren Ziemba, Judith Currier, John Shepherd, Risa Hoffman, Tapiwa Mbengeranwa, Lameck Chinula. Markers of maternal bone and renal toxicity through 50 weeks postpartum: IMPAACT 2010 (VESTED) Trial. Journal of Acquired Immune Deficiency Syndromes. 2024. 97: 172-179. PMID: 39250651Year
2024
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
IMPAACT 2010
Lamivudine Dosing for Preterm Infants Exposed to HIV: a Population Pharmacokinetic Modelling and Simulation Study
Citation
Adrie Bekker, Edmund V. Capparelli, Mark Mirochnick, Diana F. Clarke, Mark F Cotton, Roger Shapiro, Katie McCarthy, Jack Moye, Avy Violari, Kulkanya Chokephaibulkit, Elaine Abrams, Martina Penazzato, Ted Ruel, Tim R. Cressey. Lamivudine Dosing for Preterm Infants Exposed to HIV: a Population Pharmacokinetic Modelling and Simulation Study. Journal of Antimicrobial Chemotherapy. 2024. 79: 2570-2574. PMID: 39092932Year
2024
Journal
Journal of Antimicrobial Chemotherapy
Study
P1106